Umesh Patel, MD
Cardiovascular Disease · Covington, LANPI 1629070826
Payments from drug & device makers
Across 302 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$538
- Amgen$479
- Merck$457
- Johnson & Johnson$425
- Novartis$332
- Pfizer$311
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,297100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $538 |
| Amgen | 41 | $479 |
| Merck | 28 | $457 |
| Johnson & Johnson | 29 | $425 |
| Novartis | 25 | $332 |
| Pfizer | 12 | $311 |
| Sanofi-aventis U.S. LLC | 19 | $300 |
| AstraZeneca | 12 | $243 |
| Medtronic(2 entities) | 12 | $237 |
| E.r. Squibb & Sons, L.L.C. | 12 | $216 |
| Lundbeck LLC | 6 | $211 |
| Boehringer Ingelheim | 16 | $206 |
| Amarin Pharma, Inc. | 10 | $184 |
| Inspire Medical Systems, Inc. | 2 | $138 |
| Regeneron Healthcare Solutions, Inc. | 7 | $131 |
| Esperion Therapeutics, Inc. | 6 | $87 |
| Biotronik Inc. | 1 | $82 |
| Scpharmaceuticals Inc. | 4 | $73 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $72 |
| Astellas Pharma US Inc | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Abiomed | 2 | $51 |
| Bayer | 3 | $46 |
| Atricure, Inc. | 1 | $42 |
| Irhythm Technologies, Inc. | 3 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Baxter Healthcare | 2 | $35 |
| Seqirus USA Inc | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Boston Scientific | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Cvrx, Inc. | 1 | $25 |
| Medicomp Inc | 1 | $21 |
| Itamar Medical Inc | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 3 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,297 in reported general payments places this provider in the 60th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $127,097 |
| EntrestoSacubitril/Valsartan | 100 | $93,803 |
| XareltoRivaroxaban | 57 | $62,464 |
| Repatha SureclickEvolocumab | 60 | $49,580 |
| FarxigaDapagliflozin Propanediol | 32 | $42,383 |
| TrulicityDulaglutide | 33 | $40,955 |
| OzempicSemaglutide | 33 | $34,887 |
| JardianceEmpagliflozin | 31 | $32,550 |
| CorlanorIvabradine Hcl | 28 | $29,456 |
| NexletolBempedoic Acid | 36 | $23,533 |
| VerquvoVericiguat | 21 | $22,260 |
| NexlizetBempedoic Acid/Ezetimibe | 22 | $13,037 |
| Ranolazine ErRanolazine | 207 | $12,390 |
| MounjaroTirzepatide | 11 | $11,274 |
| Midodrine Hcl | 166 | $10,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $311 | $127,097150 claims |
| NovartisEntresto | $332 | $93,803100 claims |
| Johnson & JohnsonXarelto | $425 | $62,46457 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $33 | $52,22944 claims |
| AstraZenecaFarxiga | $243 | $42,38332 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $87 | $36,57058 claims |
| Novo NordiskOzempic | $538 | $34,88733 claims |
| Boehringer IngelheimJardiance | $206 | $32,55031 claims |
| AmgenCorlanor | $479 | $29,45628 claims |
| MerckVerquvo | $457 | $22,26021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Covington
- Dale PresserCovington$1.7M
- Ghiath MikdadiHammond$5.7M
- Marc BernsteinSlidell$2.1M
- Anil ChhabraShreveport$1.9M
- William EavesShreveport$1.6M
- Assad MouhaffelWest Monroe$1.4M
- Wenwu ZhangShreveport$1.1M
- William SmithRuston$694K
- Imran ChaudryMonroe$371K
- Keith FerdinandNew Orleans$335K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.